01
What changed in biotechnology regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
EMD Serono and Exelixis have implemented return-to-office mandates that resulted in workforce reductions for remote employees.
Read at biospace.com ↗03
A recent survey indicates that 71% of patients with chronic conditions are willing to participate in clinical trials, yet only 9% have ever been invited.
Read at kffhealthnews.org ↗04
The FDA is currently evaluating a new oncology clinical outcome assessment tool, highlighting the ongoing complexity and time-consuming nature of the agency's qualification process.
Read at citeline.com ↗05
The US FDA published lessons on August 19, 2026, regarding the deployment of artificial intelligence in pharmacovigilance.
Read at citeline.com ↗06
The European regulatory timeline for the spinal muscular atrophy (SMA) drug apitegromab has been delayed following a failed inspection of its fill-finish facilities.
Read at citeline.com ↗07
The Medicines and Healthcare products Regulatory Agency (MHRA) published a position paper on August 18, 2026, clarifying the regulatory framework for microbiome-based medicinal products (MBMPs) in the UK.
Read at gov.uk ↗08
The European Medicines Agency (EMA) has accepted the regulatory filing for Pfizer and Valneva's Lyme disease vaccine, marking a global first for this candidate.
Read at citeline.com ↗8 of 9 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What funding rounds and acquisitions happened in biotechnology this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
Werewolf Therapeutics has agreed to merge with Ambros Therapeutics in an all-stock deal.
Read at fiercebiotech.com ↗10
Radial, a management services organization for brain medicine clinics, is acquiring TMS Health Partners, which manages 20 clinics under Mindful Health Solutions.
Read at fiercehealthcare.com ↗11
Amgen has terminated its Crohn's disease collaboration with TScan Therapeutics.
Read at fiercebiotech.com ↗12
Tolerance Bio has entered into a licensing agreement with NeoImmuneTech to acquire rights for a fusion protein targeting thymus-related indications.
Read at fiercebiotech.com ↗13
Leo Pharma has entered into a $435 million agreement to acquire a rare skin disease drug from Tanabe Pharma.
Read at fiercebiotech.com ↗14
The AI biopharma company Craif has raised $33 million in a Series D funding round.
Read at fiercebiotech.com ↗15
BioMarin Pharmaceutical has entered into a deal with Alesta to continue its focus on genetically driven diseases.
Read at citeline.com ↗16
In 2026, at least seven biopharmaceutical companies have conducted layoffs following mergers or acquisitions, resulting in a total of at least 1,359 job losses.
Read at biospace.com ↗8 of 12 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What products launched in biotechnology this week?
Notable product launches, releases and platform updates from the week.
17
The Department of Energy’s Oak Ridge Office of Environmental Management and Isotek Systems have opened a new analytical laboratory in Building 2026 at Oak Ridge National Laboratory.
Read at ans.org ↗18
The US FDA has granted approval to Ultragenyx for its gene therapy Genglycos, intended to treat a rare glycogen storage disease.
Read at biopharmadive.com ↗19
On August 20, 2026, the FDA approved Regeneron's Pasatru for adults with fibrodysplasia ossificans progressiva, an ultra-rare disorder.
Read at pharmexec.com ↗20
BlueRock Therapeutics has developed an automated system for high-throughput analytical auditing of cell therapies.
Read at genengnews.com ↗21
Nestlé is developing a new line of tailored nutrition products specifically designed for users of GLP-1 weight-loss medications.
Read at foodnavigator.com ↗22
Insilico Medicine has launched a new Virtual Aging Cell platform designed to accelerate drug discovery processes.
Read at citeline.com ↗23
Researchers at Lawrence Berkeley National Laboratory have developed the Multimodal Optical Scope with Adaptive Imaging Correction (MOSAIC), a reconfigurable microscope that integrates over ten imaging techniques.
Read at hpcwire.com ↗24
Johnson & Johnson MedTech has received a software update for its Monarch bronchoscopy robot, marking the company's fourth major software launch in the past 18 months.
Read at fiercebiotech.com ↗8 of 10 product launches events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What financial results were reported in biotechnology this week?
Earnings, guidance and other financial results reported this week.
25
Bavarian Nordic reported a boost in its travel vaccine business, bucking broader industry trends.
Read at citeline.com ↗26
Merck and Moderna reported positive phase 3 clinical trial data for their cancer vaccine, resulting in a $45 billion increase in Moderna's market capitalization.
Read at fiercebiotech.com ↗27
Moderna saw its market value increase by $45 billion in a single day on August 20, 2026, following positive news regarding its cancer vaccine.
Read at biopharmadive.com ↗28
Moderna Inc. shares experienced a record 160% surge on August 19, 2026.
Read at bloomberg.com ↗29
JPMorgan initiated coverage of Nuvation Bio on August 18, 2026, with an Overweight rating and a price target of $13 per share through December 2027.
Read at thestreet.com ↗30
On August 17, 2026, Jefferies analyst Tycho Peterson initiated coverage of Freenome Inc. with a 'Buy' rating and a $17 price target.
Read at thestreet.com ↗31
Billionaire investor Stanley Druckenmiller increased his stake in the cancer-testing company Natera through his Duquesne Family Office.
Read at thestreet.com ↗32
Bora Pharmaceuticals reported record-high quarterly revenue of NT$5,889 million for 2Q26, representing a 47.2% increase quarter-over-quarter.
Read at treasurytoday.com ↗What court rulings and legal actions hit biotechnology this week?
Court rulings, filings and legal actions reported this week.
33
US investment group Gotham City Research has issued a second report targeting Sumitomo Pharma, raising concerns regarding the company's cell therapy research and its relationship with the Center for iPS Cell Research and Application (CiRA) in Japan.
Read at citeline.com ↗What research was published in biotechnology this week?
New research findings and studies published this week.
34
The International Atomic Energy Agency (IAEA) and the Food and Agriculture Organization (FAO) have launched a five-year coordinated research project to assess the safety of edible insects and other novel foods.
Read at foodsafetynews.com ↗35
An international team of scientists, including researchers from Harvard University, successfully grew human brain organoids in a laboratory for five years.
Read at futurism.com ↗36
Scientists in China discovered that the cowpea plant (Vigna unguiculata) uses a multi-step defense mechanism against the American serpentine leafminer (Liriomyza trifolii).
Read at gizmodo.com ↗37
Merck and Moderna announced that their Phase 3 INTerpath 001 trial for the personalized cancer vaccine intismeran autogene (V940/mRNA 4157) in combination with Keytruda met its primary endpoints for treating resected melanoma.
Read at thestreet.com ↗38
Merck & Co. and Moderna have reported successful phase 3 clinical trial results for their personalized mRNA cancer vaccine.
Read at fiercebiotech.com ↗39
Moderna and Merck announced positive Phase 3 trial results for their mRNA-based melanoma vaccine, intismeran autogene (mRNA-4157), on August 19, 2026.
Read at gizmodo.com ↗40
Researchers have achieved a breakthrough in modeling human brain development using organoids, successfully maintaining them for a period of five years.
Read at fiercebiotech.com ↗41
Researchers led by Jeffrey Bailey and Karamoko Niaré from Brown University identified new genetic mutations in Plasmodium falciparum parasites in Uganda that cause decreased susceptibility to common antimalarial drugs.
Read at genengnews.com ↗8 of 36 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What partnerships were announced in biotechnology this week?
Partnerships, integrations and joint projects announced this week.
42
UroGen Pharma has entered into an equity investment and strategic research agreement with IntraGel Therapeutics as of August 2026.
Read at pharmexec.com ↗1 of 8 partnerships events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What people moved in and out of biotechnology roles this week?
Executive appointments and departures reported this week.
43
In August 2026, multiple pharmaceutical companies including Sanofi, EMD Serono, and Emergent BioSolutions reported workforce reductions and restructuring activities.
Read at drugdiscoverytrends.com ↗1 of 5 people moves events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What else happened in biotechnology this week?
Developments from the week that fit none of the other sections.
44
Michael Polansky, founder of the startup Outer Biosciences, is developing an AI model trained on living human tissue.
Read at techcrunch.com ↗45
In 2024, licensing deals with Chinese pharmaceutical and biotech companies reached a record $51.9 billion, marking a 90% increase from 2023.
Read at pharmexec.com ↗2 of 7 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.